Revvity (NYSE:RVTY) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. disclosed selling $1,001–$15,000 of Revvity stock on September 4 from a Bank of America trust account. He also reported several other stock purchases and sales in late September and early October.
• Revvity shares opened at $155.08, down 0.3%, after the company beat quarterly earnings and revenue expectations. Management’s fiscal 2026 EPS guidance is $5.30–$5.40, while revenue declined 1.3% year over year.
• The company declared a quarterly dividend of $0.07 per share, equivalent to a 0.2% yield. Analysts remain cautious overall, with a consensus “Hold” rating and a $124.43 price target despite several recent target increases.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Revvity stock on September 4th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

Revvity Trading Down 0.3%

Shares of RVTY stock opened at $155.08 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The company has a market cap of $17.31 billion, a price-to-earnings ratio of 73.85, a PEG ratio of 2.83 and a beta of 1.06. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $166.25. The firm has a fifty day moving average price of $134.17 and a 200-day moving average price of $112.19.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The company had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. During the same period in the previous year, the business earned $1.18 earnings per share. Revvity's quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity's dividend payout ratio (DPR) is currently 13.33%.

Institutional Trading of Revvity

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ascentis Independent Advisors bought a new position in Revvity in the 1st quarter worth approximately $29,000. SJS Investment Consulting Inc. grew its holdings in Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company's stock valued at $47,000 after buying an additional 521 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of Revvity during the second quarter valued at approximately $51,000. Summit Securities Group LLC raised its position in shares of Revvity by 294.6% during the first quarter. Summit Securities Group LLC now owns 663 shares of the company's stock valued at $58,000 after buying an additional 495 shares during the last quarter. Finally, Contravisory Investment Management Inc. bought a new stake in shares of Revvity during the first quarter valued at approximately $66,000. Institutional investors own 86.65% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on RVTY shares. UBS Group started coverage on shares of Revvity in a report on Wednesday, September 9th. They issued a "neutral" rating and a $140.00 target price for the company. TD Cowen lifted their price target on shares of Revvity from $130.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday. Barclays upped their price target on shares of Revvity from $115.00 to $160.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 7th. Evercore reissued an "outperform" rating on shares of Revvity in a research note on Wednesday, August 5th. Finally, KeyCorp increased their price objective on shares of Revvity from $125.00 to $165.00 and gave the stock an "overweight" rating in a research note on Friday, September 4th. Five investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $124.43.

Insider Buying and Selling at Revvity

In related news, insider Tajinder Vohra sold 7,330 shares of the company's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the company's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the transaction, the insider owned 14,781 shares of the company's stock, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 9,130 shares of company stock worth $1,290,745 in the last three months. Insiders own 0.85% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Revvity Company Profile

Revvity, Inc NYSE: RVTY is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.